17 research outputs found
Berkeley Supernova Ia Program I: Observations, Data Reduction, and Spectroscopic Sample of 582 Low-Redshift Type Ia Supernovae
In this first paper in a series we present 1298 low-redshift (z\leq0.2)
optical spectra of 582 Type Ia supernovae (SNe Ia) observed from 1989 through
2008 as part of the Berkeley SN Ia Program (BSNIP). 584 spectra of 199 SNe Ia
have well-calibrated light curves with measured distance moduli, and many of
the spectra have been corrected for host-galaxy contamination. Most of the data
were obtained using the Kast double spectrograph mounted on the Shane 3 m
telescope at Lick Observatory and have a typical wavelength range of
3300-10,400 Ang., roughly twice as wide as spectra from most previously
published datasets. We present our observing and reduction procedures, and we
describe the resulting SN Database (SNDB), which will be an online, public,
searchable database containing all of our fully reduced spectra and companion
photometry. In addition, we discuss our spectral classification scheme (using
the SuperNova IDentification code, SNID; Blondin & Tonry 2007), utilising our
newly constructed set of SNID spectral templates. These templates allow us to
accurately classify our entire dataset, and by doing so we are able to
reclassify a handful of objects as bona fide SNe Ia and a few other objects as
members of some of the peculiar SN Ia subtypes. In fact, our dataset includes
spectra of nearly 90 spectroscopically peculiar SNe Ia. We also present
spectroscopic host-galaxy redshifts of some SNe Ia where these values were
previously unknown. [Abridged]Comment: 34 pages, 11 figures, 11 tables, revised version, re-submitted to
MNRAS. Spectra will be released in January 2013. The SN Database homepage
(http://hercules.berkeley.edu/database/index_public.html) contains the full
tables, plots of all spectra, and our new SNID template
Dapagliflozin versus metolazone in heart failure resistant to loop diuretics
Background and Aims:
To examine the decongestive effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin compared to the thiazide-like diuretic metolazone in patients hospitalized for heart failure and resistant to treatment with intravenous furosemide.
Methods:
A multi-centre, open-label, randomized, active-comparator trial. Patients were randomized to dapagliflozin 10 mg once daily or metolazone 5-10 mg once daily for a 3-day treatment period, with follow-up for primary and secondary endpoints until day 5 (96 hours). The primary endpoint was diuretic effect, assessed by change in weight (kg). Secondary endpoints included change in pulmonary congestion (lung ultrasound), loop diuretic efficiency (weight change per 40 mg of furosemide), and a volume assessment score.
Results:
61 patients were randomized. The mean (±standard deviation) cumulative dose of furosemide at 96 hours was 976 (±492) mg in the dapagliflozin group and 704 (±428) mg in patients assigned to metolazone. The mean (±standard deviation) decrease in weight at 96 hours was 3.0 (2.5) kg with dapagliflozin compared to 3.6 (2.0) kg with metolazone [mean difference 0.65, 95% confidence interval (CI) -0.12,1.41 kg; p=0.11]. Loop diuretic efficiency was less with dapagliflozin than with metolazone [mean 0.15 (0.12) versus 0.25 (0.19); difference -0.08, 95% CI -0.17,0.01 kg; p=0.10]. Changes in pulmonary congestion and volume assessment score were similar between treatments. Decreases in plasma sodium and potassium and increases in urea and creatinine were smaller with dapagliflozin than with metolazone. Serious adverse events were similar between treatments.
Conclusion:
In patients with heart failure and loop diuretic resistance, dapagliflozin was not more effective at relieving congestion than metolazone. Patients assigned to dapagliflozin received a larger cumulative dose of furosemide but experienced less biochemical upset than those assigned to metolazone.
ClinicalTrials.gov Identifier:
NCT04860011
Gly-Spec: a webtool for predicting glycan specificity by integrating glycan array screening data and 3D structure
Complement Activation in Arterial and Venous Thrombosis is Mediated by Plasmin
Thrombus formation leading to vaso-occlusive events is a major cause of death, and involves complex interactions
between coagulation, fibrinolytic and innate immune systems. Leukocyte recruitment is a key step,
mediated partly by chemotactic complement activation factors C3a and C5a. However, mechanisms mediating
C3a/C5a generation during thrombosis have not been studied. In a murine venous thrombosis model, levels of
thrombin–antithrombin complexes poorly correlated with C3a and C5a, excluding a central role for thrombin
in C3a/C5a production. However, clotweight strongly correlated with C5a, suggesting processes triggered during
thrombosis promote C5a generation. Since thrombosis elicits fibrinolysis,we hypothesized that plasmin activates
C5 during thrombosis. In vitro, the catalytic efficiency of plasmin-mediated C5a generation greatly exceeded that
of thrombin or factor Xa, but was similar to the recognized complement C5 convertases. Plasmin-activated C5
yielded a functional membrane attack complex (MAC). In an arterial thrombosis model, plasminogen activator
administration increased C5a levels. Overall, these findings suggest plasmin bridges thrombosis and the immune
response by liberating C5a and inducing MAC assembly. These new insights may lead to the development of
strategies to limit thrombus formation and/or enhance resolutionMedicine, Faculty ofNon UBCMedicine, Department ofReviewedFacult
Cardiovascular Disease Risk Factors and Left Ventricular Hypertrophy in Girls and Boys With CKD
Combining 3D structure with glycan array data provides insight into the origin of glycan specificity
Off-season RSV epidemics in Australia after easing of COVID-19 restrictions
Human respiratory syncytial virus (RSV) is an important cause of acute respiratory infection (ARI) with the most severe disease in the young and elderly1,2. Non-pharmaceutical interventions (NPIs) and travel restrictions for controlling COVID-19 have impacted the circulation of most respiratory viruses including RSV globally, particularly in Australia, where during 2020 the normal winter epidemics were notably absent3–6. However, in late 2020, unprecedented widespread RSV outbreaks occurred, beginning in spring, and extending into summer across two widely separated states of Australia, Western Australia (WA) and New South Wales (NSW) including the Australian Capital Territory (ACT). Genome sequencing revealed a significant reduction in RSV genetic diversity following COVID-19 emergence except for two genetically distinct RSV-A clades. These clades circulated cryptically, likely localized for several months prior to an epidemic surge in cases upon relaxation of COVID-19 control measures. The NSW/ACT clade subsequently spread to the neighbouring state of Victoria (VIC) and caused extensive outbreaks and hospitalisations in early 2021. These findings highlight the need for continued surveillance and sequencing of RSV and other respiratory viruses during and after the COVID-19 pandemic as mitigation measures introduced may result in unusual seasonality, along with larger or more severe outbreaks in the future
Off-season RSV epidemics in Australia after easing of COVID-19 restrictions
Human respiratory syncytial virus (RSV) is an important cause of acute respiratory infection with the most severe disease in the young and elderly. Non-pharmaceutical interventions and travel restrictions for controlling COVID-19 have impacted the circulation of most respiratory viruses including RSV globally, particularly in Australia, where during 2020 the normal winter epidemics were notably absent. However, in late 2020, unprecedented widespread RSV outbreaks occurred, beginning in spring, and extending into summer across two widely separated regions of the Australian continent, New South Wales (NSW) and Australian Capital Territory (ACT) in the east, and Western Australia. Through genomic sequencing we reveal a major reduction in RSV genetic diversity following COVID-19 emergence with two genetically distinct RSV-A clades circulating cryptically, likely localised for several months prior to an epidemic surge in cases upon relaxation of COVID-19 control measures. The NSW/ACT clade subsequently spread to the neighbouring state of Victoria and to cause extensive outbreaks and hospitalisations in early 2021. These findings highlight the need for continued surveillance and sequencing of RSV and other respiratory viruses during and after the COVID-19 pandemic, as mitigation measures may disrupt seasonal patterns, causing larger or more severe outbreaks